Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Pembrolizumab FDA Applications Resubmitted for Updated Dosing Schedule

April 23rd 2020

Supplemental biologics license applications have been resubmitted to the FDA for pembrolizumab to include an every-6-weeks option at 400 mg over 30-minute infusions across multiple indications.

Ruxolitinib REACH2 aGVHD Data Show Superiority Over Standard Care

April 23rd 2020

The REACH2 ruxolitinib acute graft-versus-host disease data have been published in the New England Journal of Medicine.

Dr. Feldman on the Utility of PET Scan in Hodgkin Lymphoma

April 23rd 2020

Tatyana Feldman, MD, discusses the utility of PET Scan in Hodgkin Lymphoma.

Dr. Bannerji on Ongoing Research With REGN1979 in Non-Hodgkin Lymphoma

April 23rd 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses ongoing research with the bispecific antibody REGN1979 in non-Hodgkin lymphoma (NHL).

Expert Highlights Novel Agents in Acute GVHD

April 23rd 2020

Mark A. Schroeder, MD, discusses emerging therapeutic strategies for patients with acute GVHD.

FDA Grants RMAT Designation to Tisagenlecleucel for Follicular Lymphoma

April 22nd 2020

The FDA has granted a Regenerative Medicine Advanced Therapy designation to tisagenlecleucel for the treatment of patients with relapsed/refractory follicular lymphoma.

Dr. Brody on the Role of Immunotherapy in Indolent Lymphomas

April 22nd 2020

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

Dr. Davies on Research Efforts in Lenalidomide-Refractory Myeloma

April 21st 2020

Faith E. Davies, MD, discusses the research being done in patients with multiple myeloma who are refractory to lenalidomide.

Bispecific Antibody Is Highly Active in Relapsed/Refractory Non-Hodgkin Lymphoma

April 20th 2020

Rajat Bannerji, MD, PhD, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma.

Dr. Kansagra on Updates With CAR T-cell Therapy in Myeloma

April 18th 2020

Ankit Kansagra, MD, discusses updates with CAR T-cell therapy in multiple myeloma.

Dr. Anderson on the GRIFFIN Study With D-RVd in Multiple Myeloma

April 18th 2020

Larry Anderson, MD, PhD, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.

Dr. Nagalla on the Utility of DOACs in Cancer-Associated Thrombosis

April 18th 2020

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in cancer-associated thrombosis.

Kreitman Highlights Moxetumomab Pasudotox Benefit in Hairy Cell Leukemia

April 17th 2020

Robert J. Kreitman, MD, discusses the long-term findings from the pivotal phase III trial with moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Dr. Kreitman on Ongoing Research With Moxetumomab Pasudotox in Hairy Cell Leukemia

April 17th 2020

Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses ongoing research with moxetumomab pasudotox-tdfk (Lumoxiti) in patients with hairy cell leukemia (HCL).

Dr. Grossbard on the DYNAMO Study With Duvelisib in Follicular Lymphoma

April 17th 2020

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

Acalabrutinib Long-Term Benefit in CLL Captured in Published Data

April 17th 2020

The benefit of single-agent acalabrutinib continued well over 3 years after treatment initiation in patients with relapsed/refractory chronic lymphocytic leukemia.

Anticoagulation Is Important Element of Adjunctive Therapy in Thrombosis Management

April 16th 2020

Alvin H. Schmaier, MD, discusses the primary and secondary management of cancer-related thrombosis.

Dr. Brody on Tolerability of In-Situ Vaccines in Indolent Non-Hodgkin Lymphoma

April 16th 2020

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Dr. Cutler on Novel Preventive Strategies Against GVHD

April 16th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin Lymphoma

April 16th 2020

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.